United Kingdom Cell & Gene Therapy Cold Chain Logistics Market to be Dominated by Transportation Type Service Segment through 2028
Increasing demand for cell and gene
therapies, development of advanced cold chain technologies and solutions, and
presence of a strong research and innovation ecosystem are
factors that drives United Kingdom cell & gene
therapy cold chain logistics market in the forecast period 2024-2028
According to TechSci Research report, “United Kingdom Cell
& Gene Therapy Cold Chain Logistics Market - Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028”, United Kingdom Cell & Gene Therapy Cold Chain Logistics Market Size
is anticipated to increase at a substantial rate in the forecast period.
The supportive regulatory environment and
government initiatives are expected to propel the growth of the United
Kingdom's cell and gene therapy cold chain logistics market. These initiatives
have helped to position the United Kingdom as a global leader in the cell and
gene therapy industry and have provided a clear path to market for these
therapies. As the sector continues to grow, it is expected to see further
investment and innovation in cold chain logistics technologies and solutions,
enabling the safe and efficient delivery of these life-changing therapies to
patients. Moreover, the use of advanced technologies such as adoption of
automation and robotics, real-time monitoring and tracking, cloud-based
logistics management systems, blockchain technology, and AI and ML is enabling
logistics providers to improve their efficiency, accuracy, and safety of
transporting these therapies is transforming the United Kingdom's cell and gene
therapy cold chain logistics market. As the demand for cell and gene therapies
continues to grow, it is expected that the further technological advancements
and innovations in the logistics processes will happen to ensure the safe and
efficient transportation of these life-changing therapies to patients in need.
At the identical time, the cell &
gene therapy cold chain logistics market in United Kingdom faces several
challenges such as maintaining the cold chain, lack of standardization, transportation
costs, and need of skilled worker. The transportation of cell and gene
therapies is costly due to the specialized equipment and requirements needed to
maintain the cold chain. The cost of transportation can be a significant
challenge, especially for small companies or organizations with limited
resources. Beside this, there is a lack of standardization in the industry,
making it challenging for logistics providers to develop consistent processes
for transporting cell and gene therapies. The lack of standardization can
result in inconsistencies in transportation processes, increasing the risk of
temperature deviations or other issues.
Browse over XX market data Figures spread through XX Pages and an in-depth
TOC on the "United Kingdom Cell and Gene Therapy Cold Chain Logistics Market.”
United Kingdom Cell & Gene Therapy Cold Chain Logistics market is segmented
based on component, services offered, mode of transportation, holding
temperature range, end user, and region.
Based on the service offered,
the market is divided into transportation, storage,
and packaging. The
transportation segment is expected to hold the largest market share in the
forecast period due to the high demand for transporting cell and gene therapy
products across different the world. These products require strict temperature
control and monitoring to ensure their quality and efficacy during
transportation from hospital or research institution.
Based on the end user, the
market is divided into pharmaceutical & biotechnology companies, academic
& research institutes, and others. The pharmaceutical & biotechnology companies’
segment is expected to hold the largest market share in the forecast period
due to the high demand for these
therapies from patients with chronic and rare diseases. Pharmaceutical &
biotechnology companies are investing heavily in research and development of
cell and gene therapies, as well as in manufacturing and distribution
facilities that require cold chain logistics. These companies also have the
expertise and resources to ensure the quality and safety of these therapies
throughout the supply chain. Therefore, they are the leading end users of Cell
& Gene Therapy Cold Chain Logistics services.
Major companies operating
in the United Kingdom Cell & Gene Therapy Cold Chain Logistics market are:
- Atelerix Ltd.
- Life Science Group Ltd (LSG)
- Arvato Group
- DGP Intelius Ltd.
- QuickSTAT (A Kuehne + Nagel Company)
- BIOCAIR
- TrakCel
- Cryoport UK Limited
- Patheon UK Limited (Thermo Fischer
Scientific UK)
- Catalent UK
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
“United Kingdom cell and gene therapy cold chain logistics market is evolving
rapidly due to the increasing demand for these therapies. Several trends are
driving the market growth, including the adoption of automation and robotics in
logistics processes, real-time monitoring and tracking technologies,
cloud-based logistics management systems, blockchain technology, and artificial
intelligence and machine learning. These advanced technologies enable logistics
providers to optimize their processes, reduce transportation costs, and ensure
the safety and efficiency of transporting cell and gene therapies. However,
there are still several challenges facing the industry, such as maintaining the
cold chain, transportation costs, regulatory compliance, limited infrastructure,
and lack of standardization. To overcome these such challenges, logistics
providers must invest in advanced technologies and innovative solutions to
ensure the safe and efficient transportation of cell and gene therapies to
patients.” said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based global management consulting firm.
United Kingdom Cell
& Gene Therapy Cold Chain Logistics Market, By Component (Cryogenic
Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management
Systems, Shipment and Storage Medium, Cryogenic Packout Kits Others {Shipment
Containers, Reusable Boxes, etc.}), By Services Offered (Transportation,
Storage, Packaging), By Mode of Transportation (Air, Ground, Water), By Holding
Temperature Range (Cryogenic, Refrigerated, Ambient, Others {Deep Freezers, Dry
Ice, etc.}), By End User (Pharmaceutical & Biotechnology Companies,
Academic & Research Institutes, Others), By Region, Competition, Forecast
& Opportunities, 2018-2028F, has evaluated the future growth potential of United Kingdom
cell & gene therapy cold chain logistics market and provides statistics
& information on market size, structure, and future market growth. The
report intends to provide cutting-edge market intelligence and help decision
makers take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in United Kingdom cell & gene therapy cold chain logistics market.”
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com